Last reviewed · How we verify
lapatinib plus oral vinorelbine
At a glance
| Generic name | lapatinib plus oral vinorelbine |
|---|---|
| Also known as | Tykerb, Navelbine |
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine
- Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer (PHASE2)
- Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer (PHASE1, PHASE2)
- Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer (PHASE1, PHASE2)
- A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients (PHASE2)
- Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer (PHASE1)
- Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer (PHASE1)
- Chemotherapeutic Agents in Brain/Breast
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lapatinib plus oral vinorelbine CI brief — competitive landscape report
- lapatinib plus oral vinorelbine updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI